NMPA Approves Marketing Update for Baiyunshan's Drug Products
China’s NMPA approves marketing update for Baiyunshan's Pseudoephedrine Granules and Paracetamol.
The National Medical Products Administration has approved a
supplementary medication application for Guangxi Baiyunshan Yingkang
Pharmaceutical Co., Ltd., a subsidiary of Guangzhou Baiyunshan Pharmaceutical
Holdings Company. The permission relates to a modification in the topic of the
drug marketing authorisation for their product, Pseudoephedrine Granules and
Compound Paracetamol. The company's product portfolio is taking a significant
stride forward with this regulatory milestone.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
More from Pharma News
All stories →
Alembic Pharma Gains FDA Approval for Generic Ciprodex Otic Suspension in U.S. Market
Viatris Gains FDA Approval for RYZUMVI in Presbyopia, Expanding Phentolamine Ophthalmic Indications
Discussion